📰 INBX: Inhibrx's INBRX-106 Doubles Response Rate in Phase 2 HNSCC, Hits 9.6-Month PFS

News: Reuters

Ticker: INBX | Score: 9/10 | Sentiment: Positive

Summary (Wiseek AI)

Inhibrx reported strong Phase 2 data for INBRX-106 in head and neck squamous cell carcinoma (HNSCC). The combination with pembrolizumab achieved a 48.3% confirmed overall response rate, nearly double the historical ~25% for pembrolizumab alone, and an interim median progression-free survival of 9.6 months. The company will expand the study by 50 HPV+ patients and explore combinations with cancer vaccines and other immunogenic tumors. This is the first efficacy readout for INBRX-106 and materially de-risks the program, which could address a large market with limited options. The data also supports the company's broader oncology pipeline beyond ozekibart, whose BLA is under FDA review with an April 2027 PDUFA date. Watch for updated durability data and the planned NSCLC perioperative readout targeted for mid-2027.

Further Research: 🤖 Wiseek AI Analysis | 📰 Original Article

Automated via Wiseek.ai — Identifying market-moving SEC filings & news.